COMMUNIQUÉS West-GlobeNewswire

Akcea Reports Financial Results and Highlights for Third Quarter 2018
05/11/2018
TEGSEDI TM (inotersen) Approved in United States, European Union & Canada $320 million to fund the company through key milestones Conference Call Webcast Monday, November 5, 4:30 p.m. ET at www.akceatx.com BOSTON, [...]
Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
05/11/2018
NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases [...]
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
05/11/2018
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter [...]
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
05/11/2018
NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing [...]
MRI Interventions, Inc. to Announce Third Quarter 2018 Results on November 12
05/11/2018
IRVINE, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will release financial results for its 2018 third quarter, which ended September 30, 2018, on Monday, November 12 [...]
Evolus Reports Third Quarter 2018 Financial Results
05/11/2018
- Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - IRVINE, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. ( [...]
Neos Therapeutics Announces Proposed Offering of Common Stock
05/11/2018
DALLAS and FORT WORTH, Texas, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative [...]
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
05/11/2018
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended [...]
REVA Medical Reports Third Quarter 2018 Financial Results
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update [...]
Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018
05/11/2018
EAST RUTHERFORD, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage [...]
Novo Nordisk A/S - Share repurchase programme
05/11/2018
Bagsværd, Denmark, 5 November 2018 - As part of the up to DKK 15 billion 2018 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.2 billion in [...]
Novo Nordisk A/S purchases B shares worth DKK 1,262 million from Novo Holdings A/S under the 2018 share repurchase programme
05/11/2018
Bagsværd, Denmark, 5 November 2018 - Novo Nordisk A/S has today entered into an agreement to purchase 4,401,051 B shares (nominal DKK 0.20) of a value of DKK 1,262 million from Novo Holdings A/S. This transaction is [...]
FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
05/11/2018
EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of [...]
Phoenix Life Sciences International Receives Approval for Name Change, Symbol Change, and Completion of Consolidation of Businesses
05/11/2018
DENVER, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced it has completed the last [...]
VALNEVA : Déclaration d'actions et de droits de vote - OCTOBRE 2018
05/11/2018
VALNEVA Déclaration d'actions et de droits de vote - OCTOBRE 2018 Dénomination sociale : VALNEVA Adresse du siège social : 6 rue Alain Bombard, 44800 Saint-Herblain Marché réglementé Euronext Paris de Nyse Euronext - [...]
Sanofi: Disclosure of trading in own shares
05/11/2018
Attachment Reporting EN.pdf
Sanofi : Déclaration des transactions sur actions propres
05/11/2018
Pièce jointe Reporting FR.pdf
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018
05/11/2018
LYON, France, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 octobre 2018
05/11/2018
LYON, France, 05 nov. 2018 (GLOBE NEWSWIRE) -- Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Lyon - France Places de cotation : Euronext Paris de Euronext (Compartiment B - Code ISIN : [...]

Pages